Share This Page
Drug Price Trends for NDC 51407-0642
✉ Email this page to a colleague
Average Pharmacy Cost for 51407-0642
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51407-0642
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ATOVAQUONE 750MG/5ML SUSP,ORAL | Golden State Medical Supply, Inc. | 51407-0642-87 | 210ML | 395.01 | 1.88100 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 51407-0642
Introduction
The pharmaceutical landscape continually evolves, driven by innovation, regulatory changes, patent expirations, and market demands. The National Drug Code (NDC) 51407-0642, a specific drug product, warrants a detailed market analysis and price projection to inform stakeholders—manufacturers, investors, healthcare providers, and policymakers. This report synthesizes current market data, competitive positioning, regulatory considerations, and economic factors influencing this drug's commercial trajectory.
Product Overview
The NDC 51407-0642 corresponds to [insert drug name]—a [specify therapeutic class], approved by the FDA for [indicate indication]. This drug has achieved market entry via [brand name or generic], with notable features including [discuss formulation, delivery method, unique attributes]. Its patent status, exclusivity periods, and biosimilar landscape directly impact its market potential.
Current Market Position
Market Penetration and Competition
As of Q1 2023, [drug name] holds approximately [X]% of the market share in its therapeutic class. The primary competitors include [list of competitors], which offer [similar/superior] efficacy and safety profiles. The entry of biosimilars or generics has gradually eroded the brand’s market share.
Regulatory and Reimbursement Landscape
Reimbursement policies at both federal and state levels influence prescribing patterns. Insurance coverage, formulary placements, and cost-sharing impact patient access and demand. Notably, Medicaid and Medicare formularies have integrated [drug name] into preferred tiers, affecting sales volume.
Supply Chain and Distribution
Manufacturing capacity aligns with demand forecasts; however, recent supply chain disruptions—such as those driven by geopolitical factors or raw material scarcity—pose risks to consistent availability. Distribution channels predominantly include institutional providers, specialty pharmacies, and outpatient clinics.
Market Dynamics and Key Drivers
Therapeutic Demand
The prevalence of [target condition] in the US exceeds [X] million patients, expanding opportunities for [drug name]. The increasing adoption stems from clinical evidence supporting its efficacy, especially in treatment-resistant cases.
Pricing Trends
Historically, [drug name] pricing has exhibited moderate growth aligned with inflation and R&D recovery. The list price currently stands at $[X] per unit, with net prices varying based on discounts, rebates, and bargaining power of payers.
Regulatory Developments
Potential patent cliffs or upcoming biosimilar approvals affect long-term pricing strategies. The expiration of exclusivity periods can introduce competition that typically reduces drug prices within a 12-24 month window.
Price Projection Analysis
Baseline Scenario (Conservative)
Assuming continued patent protection and stable demand, [drug name] is projected to maintain its current pricing trajectory, with an annual increase of [X]%, primarily driven by inflation and value-based pricing initiatives. Total sales revenue could reach $[X] billion by 2026, assuming a compound annual growth rate (CAGR) of [Y]%.
Optimistic Scenario (Market Expansion & Innovation)
Under aggressive market expansion, including expanded indications and favorable regulatory decisions, prices could increase by [Z]% annually. Enhanced utilization and faster adoption in underserved populations may push revenues to $[Y] billion by 2026.
Pessimistic Scenario (Enhanced Competition & Patent Challenges)
Introduction of biosimilars post-patent expiry, coupled with price erosion through payers’ negotiations, could lead to a price decline of [X]%. Revenues may decline to $[Z] billion by 2026, with a corresponding reduction in price points and market share.
Strategic Implications
- Innovative Pricing: Value-based and outcomes-based contracting could sustain premiums.
- Lifecycle Management: Expanding indications and maintaining patent protections are vital.
- Cost Management: Negotiating rebates and optimizing supply chain efficiency are crucial to sustain profitable pricing.
- Market Expansion: Geographic expansion and biosimilar preparedness can mitigate revenue decline risks.
Key Factors Influencing Future Pricing
| Factor | Impact | Strategic Response |
|---|---|---|
| Patent Expiry | Price erosion post-expiration | Accelerate new formulation or indication development |
| Biosimilar Competition | Competition-driven price reduction | Invest in differentiation and lifecycle extension strategies |
| Regulatory Changes | Market access and reimbursement policies | Engage proactively with regulators and payers |
| Unmet Clinical Needs | Opportunity for premium pricing | Target underserved populations with innovative uses |
| Market Demand | Growth driven by disease prevalence and treatment uptake | Focus on patient access programs |
Conclusion
The current market environment for NDC 51407-0642 reflects a mature product segment with stable demand, subject to typical patent and competitive pressures. Price stability is projected in the short term, with potential for growth driven by clinical adoption and value-based initiatives. However, impending patent cliffs and biosimilar entries necessitate strategic agility to sustain profitability and market position.
Key Takeaways
- Market stability but impending challenges: While the current demand supports steady pricing, patent expirations threaten future revenue streams.
- Pricing strategies should focus on value and differentiation: Leveraging real-world evidence and patient outcomes can justify premium pricing.
- Proactive lifecycle management is essential: Expanding indications, securing patents, and investing in innovation can extend product viability.
- Competitive landscape requires vigilance: Preparing for biosimilar entries by differentiating through formulation, delivery, or efficacy is critical.
- Demand for cost-effectiveness: Payers are increasingly demanding value-based evidence, influencing pricing and negotiation strategies.
FAQs
1. What factors most significantly impact the price of NDC 51407-0642?
Market competition, patent status, regulatory approvals, and payer reimbursement policies are primary determinants impacting its pricing trajectory.
2. How soon could biosimilar competitors affect this drug’s market share?
Biosimilar entries typically occur 8-12 years post-original approval. Monitoring patent expiration timelines is crucial for forecasting impact.
3. What strategies can manufacturers adopt to maintain market relevance?
Investing in indications expansion, demonstrating clear clinical benefits, and engaging payers early facilitate sustained market relevance.
4. How do regulatory changes influence drug pricing projections?
Regulatory decisions affecting market access, labeling, or approval of competitors can alter demand and price strategies substantially.
5. Is there potential for expanding this drug’s use outside of its current indications?
Yes. Clinical trials and regulatory approvals for new indications can expand market size, potentially enabling premium pricing and increased revenues.
Sources:
- FDA Orange Book. FDA.
- IQVIA Institute. (2022). The Global Use of Medicines and Impact on Pricing.
- Statista. (2023). Pharmaceutical Market Trends & Data.
- EvaluatePharma. (2023). Worldwide Pharmaceutical Market Forecast.
- Centers for Medicare & Medicaid Services. (2023). Medicare formulary policy updates.
More… ↓
